首页> 外文期刊>Genetic testing and molecular biomarkers >Molecular Study of the PCA3 Gene: Genotypic Analysis of PC A3 Polymorphism -845G>A and Metastatic Prostate Cancer
【24h】

Molecular Study of the PCA3 Gene: Genotypic Analysis of PC A3 Polymorphism -845G>A and Metastatic Prostate Cancer

机译:PCA3基因的分子研究:PC A3多态性-845G> A与转移性前列腺癌的基因型分析

获取原文
获取原文并翻译 | 示例
           

摘要

Aims: The prostate cancer gene 3 (PCA3) is a prostate-specific, non-protein-coding RNA. It is overexpressed in prostate cancer compared with the normal prostate and has a negative expression in other tissues. This case-control study sought to analyze the frequency of the polymorphism PCA3 -845 G > A in participants without prostate cancer and patients with metastatic prostate cancer. Results: Carriers of GA and AA genotype had a higher risk for metastatic prostate cancer (odds ratio [OR] for genotype GA, 1.79 [95% confidence interval (CI), 1.14-2.29]; p = 0.007; OR for genotype AA, 2.38 [95% CI, 1.22-4.65]; p = 0.006). Furthermore, the recessive model showed that A allele carriers have an increased risk for developing metastatic prostate cancer (OR, 1.91 [95% CI, 1.26-2.90]; p=0.001). Conclusions: These results suggest a link between PCA3 and metastatic prostate cancer. The evaluation of individual genetic profiles, according to the PC A3 -845 G > A polymorphism, may elucidate the function of this gene and the mechanisms involved in its regulation and role in prostate cancer.
机译:目的:前列腺癌基因3(PCA3)是一种前列腺特异的非蛋白质编码RNA。与正常前列腺相比,它在前列腺癌中过表达,并且在其他组织中具有阴性表达。这项病例对照研究旨在分析无前列腺癌参与者和转移性前列腺癌患者中PCA3-845 G> A多态性的频率。结果:GA和AA基因型的携带者罹患转移性前列腺癌的风险更高(GA基因型的比值比[OR]为1.79 [95%置信区间(CI),1.14-2.29]; p = 0.007; AA基因型为OR, 2.38 [95%CI,1.22-4.65]; p = 0.006)。此外,隐性模型显示等位基因携带者罹患转移性前列腺癌的风险增加(OR为1.91 [95%CI,1.26-2.90]; p = 0.001)。结论:这些结果表明PCA3与转移性前列腺癌之间存在联系。根据PC A3 -845 G> A多态性,对单个基因谱的评估可能阐明了该基因的功能以及其调控和在前列腺癌中的作用的机制。

著录项

  • 来源
    《Genetic testing and molecular biomarkers》 |2012年第5期|p.418-422|共5页
  • 作者单位

    Molecular Oncology Group, Portuguese Institute of Oncology of Porto, Porto, Portugal;

    Molecular Oncology Group, Portuguese Institute of Oncology of Porto, Porto, Portugal;

    Department of Urology, Sao Joao Hospital, University of Porto Medical School, Porto, Portugal;

    Portuguese Institute of Oncology of Porto, Porto Francisco Gentil, Porto, Portugal;

    Military Hospital of Porto D. Pedro V, Porto, Portugal,Hospital of Santo Antonio, Porto, Portugal;

    Central Hospital of Lisboa (Central Region), Lisboa, Portugal;

    Molecular Oncology Group, Portuguese Institute of Oncology of Porto, Porto, Portugal,CEBIMED, Healthy Sciences Faculty, Fernando Pessoa University, Porto, Portugal,LPCC, Portuguese League Against Cancer, Nucleo Regional do Norte, Porto, Portugal;

  • 收录信息 美国《科学引文索引》(SCI);美国《化学文摘》(CA);
  • 原文格式 PDF
  • 正文语种 eng
  • 中图分类
  • 关键词

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号